Moderna
-
healthEurope Approves Moderna's First mRNA Flu-COVID Vaccine, mCOMBRIAX
Moderna's mCOMBRIAX, the world's first mRNA combo vaccine for flu and COVID-19, receives European authorization, offering a simplified immunization option.
-
healthModerna Launches Phase 3 Bird Flu Vaccine Trial Amid Pandemic Concerns
Moderna's investigational mRNA-based H5 influenza vaccine, mRNA-1018, enters Phase 3 trials in the US and UK to assess pandemic preparedness.
-
techOpenAI Unveils GPT-Rosalind for Life Sciences Breakthroughs
OpenAI introduces GPT-Rosalind, an AI model designed to accelerate research in biology, drug discovery, and medicine by enhancing scientific workflows and reasoning.
-
healthSanofi Taps Belén Garijo: Pharma Regulatory Shifts and Nipah Virus Vaccine Advance
Sanofi appoints Belén Garijo as CEO, the FDA revises trial requirements, and progress accelerates on a Nipah virus vaccine, highlighting key pharma innovations in February 2026.
-
healthModerna's Spirit of Innovation Diminished by Regulatory Uncertainty
A former Moderna executive laments the shift from rapid vaccine development to a climate of regulatory unpredictability and its impact on future health innovations.
-
healthFDA Reverses Moderna Flu Shot Rejection Amidst Controversy
The FDA is now reviewing Moderna's mRNA flu vaccine application after an initial rejection, following a revised submission strategy and ongoing debate over mRNA technology.
-
healthFDA Reverses Decision, Agrees to Review Moderna's New Flu Vaccine
The US FDA will now review Moderna's mRNA-based flu shot after initially rejecting the application, signaling a shift in regulatory approach.